Evaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndrome

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 27, Issue 2, 2007, Pages 142-144

  Song, Yu'E ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Acute coronary syndrome; Efficacy; Safety; Tirofiban

Indexed keywords

ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; HEPARIN; TIROFIBAN; TYROSINE;

ACUTE CORONARY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADOLESCENT; ADULT; AGED; ANGINA, UNSTABLE; DOUBLE-BLIND METHOD; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME; TYROSINE;

EID: 34248596465     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-007-0208-9     Document Type: Article

References (7)

1. Stone G W, Moliterno D J, Bertrand M et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein II b/IIIa inhibitors in patients undergoing coronary stenting: The TARGET Trial. Circulation, 2002; 105(20):2347-2354
2. Crouch M A, Nappi J M, Cheang K I. Glycoprotein II b/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome. Ann Pharmacother, 2003, 37:860-875
3. Kim J H, Jeong M H, Rhew J Y et al. Long-term clinical outcomes of platelet glycoprotein II b/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome. Cire J, 2005, 69(2): 159-164
4. The RESTORE investigators. Effects of platelet glycoprotein II b/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997;96(5): 1445-1453
5. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein II b/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med, 1998, 338(21):1488-1497
6. Boersma E, Harrington R A, Moliterno D J et al. Platelet glycoprotein II b/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet, 2002, 359(19):189-198
7. Tcheng J E, Ellis S E, George B S et al. Pharmacodynam-ics of chimeric glycoprotein II b/IIIa integrin anti-platelet anti-body Fab 7E3 in high-risk coronary angioplasty. Circulation, 1994;90(4):1757-1764